Favorable course of Lance-Adams postanoxic action myoclonus;Syndrome de Lance et Adams d'évolution favorable

Revue Neurologique

Volumn 159, Issue 1, 2003, Pages 74-76

  Errguig, L ^a   Benomar, A ^a   Messouak, W ^a   Regragui, W ^a   Benabdejlil, M ^a   Yahyaoui, M ^a   Chkili, T ^a  

^a IBN SINA HOSPITAL   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

PIRACETAM; VALPROIC ACID;

ADULT; ANOXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DATA ANALYSIS; DISEASE COURSE; ELECTROPHYSIOLOGY; HUMAN; LANCE ADAMS SYNDROME; LARYNX SPASM; MALE; MEDICAL DECISION MAKING; MYOCLONUS; PHYSICAL ACTIVITY; POSTANOXIC ACTION MYOCLONUS; VOLUNTARY MOVEMENT;

ANTICONVULSANTS; DISEASE PROGRESSION; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; HUMANS; HYPOXIA, BRAIN; LARYNGISMUS; MALE; MIDDLE AGED; MYOCLONUS; NOOTROPIC AGENTS; PIRACETAM; VALPROIC ACID;

EID: 18344414666     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. BOURRIN JC, CHOPARD JL, LASSAUGE F, BOILLOT A, DINTROZ M, ROUSSELOT JP. (1982). Syndrome de Lance et Adams: rapport d'une observation, évolution favorable sous traitement. Lion Médical, 247: 39-43.
2. CASTAIGNE P, CAMBIER J, ESCOUROLLE R, CATHALA HP, LECASBLE R. (1964). Observation anatomoclinique d'un syndrome myoclonique post-anoxique. Rev Neurol, 111: 60-73.
3. FEDI M, REUTENS D, DUBEAU F, ANDERMANN E, D'AGOSTINO D, ANDERMANN F. (2001). Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol, 58: 781-786.
4. GENTON P, GELISSE P. (2000). Antimyoclonic effect of levetiracetam. Epileptic Disord, 2: 209-212.
5. GOULON M, HAUW JJ, VERCKEN JB, et al. (1986). Encéphalopathie anoxique après inefficacité cardio-circulatoire. In: SRLF, ed. Les comas. Paris: Expansion Scientifique, 37-64.
6. HAUW JJ, ESCOUROLLE R, BAULAC M, MOREL-MAROGER A, GOULON M, CASTAIGNE P. (1986). Postmortem studies on posthypoxic and post-methyl bromide intoxication: case reports. Adv Neurol, 43: 201-214.
7. LANCE JW, ADAMS RD. (1963). The syndrome of intention or action myoclonus as a sequallae to hypoxic encephalopathy. Brain, 86: 111-36.
8. LHERMITTE F, TALAIRACH J, BUSER P et al. (1971). Myoclonies d'intention et d'action post-anoxiques: étude stéréotaxique et destruction du noyau ventral latéral du thalamus. Rev Neurol, 124: 5-20.
9. LIRON L, CHAMBOST M, DEPIERRE P, PEILLON D, COMBE C. (1998). Efficacité de l'acide valproïque sur les myoclonies d'action postanoxiques (syndrome de Lance et Adams). Ann Fr Anesth Réanim, 17: 1247-9.
10. NIESPODZIANI I, KLITGAARD H, MARGINEAUNU DG. (2001). Levetiracetam inhibits the high-voltage-activated Ca (2+) current in pyramidal neurons of rat hippocampal slices. Neurosci Lett, 306: 5-8.
11. RICHARDSON JC, REWCASTLE NB, DE LEAN J. (1977). Hypoxic myoclonus: clinical and pathological observations. In: Rose FC ed. Physiopathological aspects of clinical neurology. Oxford: Blackwell, 231-245.
12. ROLLINSON DR, GILLIGAN SB. (1979). Post-anoxic myoclonus (Lance Adams syndrome) responding to valproate. Arch Neurol, 36.
13. SHIOTANI T, NAKAMOTO Y, WATABE S, YOSHII M, NABESHIMA T. (2000). Anticonvulsivant actions of nefiracetam on epileptic EL mice Brain Res, 859: 255-261.
14. WICKLEIM EM, SCHWENDEMANN G. (1993). Use of clonazepam and sodium valproate in patients with Lance Adams syndrome. JR Soc Med, 8:618.